Posts Tagged ‘antiobesity pills’


May 8th, 2012

Persistent Concerns About Lorcaserin (Lorqess) from FDA Reviewers

The FDA has posted briefing documents for Thursday’s meeting of the Endocrinologic and Metabolic Drugs Advisory Committee to reconsider the new drug application for lorcaserin (Lorqess, Arena). The reviewers do not appear to have substantially altered their view of lorcaserin.

December 8th, 2010

Third Time’s the Charm: FDA Panel Finally Backs an Obesity Pill

Following rejections earlier this year of two previous anti-obesity drugs, the FDA’s Endocrinologic and Metabolic Drugs advisory committee has recommended approval for Contrave, the combination of sustained-release formulations of naltrexone and buproprion from Orexigen Therapeutics. The committee voted 13-7 in favor of the drug, saying that the benefits of Contrave outweighed its risks. The committee also […]